A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous 140 mg AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed 2-4 Prophylactic Treatments (LIBERTY)

Read full text Summarise with VIRAT
Authors: Novartis
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.

Fields of Study & Subjects

Migraine and Headache Studies Pain Mechanisms and Treatments Intracranial Aneurysms: Treatment and Complications

Publication details

Journal / source
Vivli
Publication date
27 March 2026
Language
EN
Document type
Dataset